Subcutaneous implanted system for the treatment of type 2 diabetes.
10.3881/j.issn.1000-503X.2011.04.025
- Author:
Yan LI
1
;
Hui GUO
Author Information
1. Department of Endocrinology, The First Hospital of Jilin University, Changchun, China.
- Publication Type:Journal Article
- MeSH:
Diabetes Mellitus, Type 2;
drug therapy;
Humans;
Hypoglycemic Agents;
administration & dosage;
therapeutic use;
Insulin;
administration & dosage;
therapeutic use;
Insulin Infusion Systems
- From:
Acta Academiae Medicinae Sinicae
2011;33(4):473-477
- CountryChina
- Language:Chinese
-
Abstract:
Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia arising from a combination of insufficient insulin secretion and resistance to insulin action. Insulin has become an important agent in treating this disease, but long-term administration of insulin not only brings pain and inconvenience to the patients but also causes local adipose tissue atrophy and scleroma. Therefore, novel delivery method has become a hot topic, mainly including improving delivery systems, developing new recombinant insulin, and changing the route of administration. This article introduces DUROS (an implanted delivery system), a new route of drug administration.
